NCT02311673View on ClinicalTrials.gov

Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 19, 2015

Primary Completion Date

October 26, 2016

Study Completion Date

October 26, 2016

Conditions
Prader-Willi Syndrome
Interventions
DRUG

Setmelanotide

subcutaneous injection

DRUG

Placebo

Subcutaneous injection

Trial Locations (5)

11501

Winthrop University Hospital, Mineola

32610

University of Florida, Gainesville

37203

Vanderbilt University, Nashville

66160

Kansas University Medical Center, Kansas City

92617

University of California Irvine, Irvine

All Listed Sponsors
lead

Rhythm Pharmaceuticals, Inc.

INDUSTRY

NCT02311673 - Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome | Biotech Hunter | Biotech Hunter